Lipocine Inc. Announces Virtual R&D Event to Discuss LPCN 1154 as a Treatment for Postpartum Depression, Highlighting New Phase 3 Study Launch
Lipocine Inc. $(LPCN)$, a biopharmaceutical company, has announced an upcoming virtual research and development investor event scheduled for July 9, 2025. The event will discuss LPCN 1154 (BRLIZIO™), a treatment for postpartum depression $(PPD)$. The presentation will feature Dr. Kristina M. Deligiannidis from Zucker Hillside Hospital, Northwell Health, New York, along with company management, who will discuss the current treatment landscape and unmet needs in PPD. Lipocine's LPCN 1154 is noted for its potential as the first line option for rapid symptom relief in women with PPD, with a 48-hour treatment duration in an outpatient setting through an oral form. The event will include updates on clinical, regulatory, and development aspects, particularly focusing on the recently initiated Phase 3 registrational study, which is expected to yield results in Q2-2026. A live Q&A session will follow the presentations.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lipocine Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA14654) on June 23, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.